ΜΑΜΟΥΝΑΣ ΙΩΑΝΝΗΣ | Διδάκτωρ Της Ψυχιατρικής Του Πανεπιστημίου Αθηνών - Άγχος - Αγχώδεις Διαταραχές – Κατάθλιψη - Αϋπνία & Άλλες Διαταραχές Ύπνου - Γνωσιακή Ψυχοθεραπεία - Θεραπεία Οικογένειας – Ζεύγους-Ψυχαναγκασμοί - Βουλιμία - Ανορεξία, Ψυχίατροι ...
![Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6603945/MediaObjects/41416_2007_Article_BF6603945_Fig1_HTML.gif)
Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer
![6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.,The Lancet - X-MOL 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.,The Lancet - X-MOL](https://xpic.x-mol.com/20190629%2F10.1016_S0140-6736%2819%2930650-6.jpg)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.,The Lancet - X-MOL
![Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ... Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...](https://ars.els-cdn.com/content/image/1-s2.0-S1470204513705540-gr2.jpg)